Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Filings indexed 821 across all filing types
Latest filing 2024-11-13 Major Shareholding Noti…
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2024-11-13 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-13 English
10-Q
Interim / Quarterly Report Q3 2024
2024-11-07 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 6, 2024, by Collegium Pharmaceutical, Inc. It reports two main items: (1) the appointment of a new Chief Executive Officer, including detailed information about the executive's background, employment agreement, and compensation; and (2) a reference to a press release announcing quarterly financial results, but the financial results themselves are not included in this document. The document also mentions an earnings presentation and press releases attached as exhibits, but these are not the main content of the filing. The primary substantive content is the announcement of a change in senior management (CEO appointment). According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document is not a full financial report, earnings release, or other report type. Therefore, the correct classification is MANG with high confidence.
2024-11-07 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-09-17 English
Regulatory Filings 2024
Regulatory Filings
2024-09-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.